Tripos and Elsevier MDL form strategic alliance
Companies to provide integrated solutions, creating compelling discovery informatics platform for life sciences.
Boston, MA, August 10, 2005 - Tripos, Inc. (Nasdaq: TRPS) and Elsevier MDL announced today at the Drug Discovery Technology® and Development World Congress conference in Boston that they have formed a strategic alliance to strengthen the integration between their respective software products, including new-generation MDL® Isentris® technology and Tripos’ Benchware® suite of laboratory informatics software. The collaboration between Tripos and Elsevier MDL creates a powerful, integrated discovery informatics platform for the companies’ joint customers.
Under the agreement, Tripos becomes a Strategic Member of the MDL® Isentris® Alliance, and Elsevier MDL joins the Tripos Alliance Program as a Global Strategic Partner. The companies will each receive training, software and other support to ensure delivery of quality integration between the companies’ respective products. Financial terms of the alliance agreement were not disclosed.
“Tripos and Elsevier MDL share a commitment to work closely together for the benefit of our joint customers,” said Lars Barfod, Chief Executive Officer, Elsevier MDL. “Our new relationship with Tripos strengthens the Isentris Alliance, and facilitates the integration of data and workflow between our products—which is something that customers have been asking for. And our customers’ research will benefit from the combination of key enterprise informatics and data integration technology with world-class computational capabilities.”
“As we continue to expand the scope of our software portfolio, including applications and tools to analyze research results from biology, pharmacology and other scientific disciplines, it is inevitable that our applications must integrate with a range of software from leading informatics suppliers,” said Dr. John McAlister, President and Chief Executive Officer, Tripos. “Elsevier MDL is a key player in this area, and this alliance reflects Tripos’ ongoing commitment to our customers to deliver integrated discovery informatics solutions that are critical to the success of their research programs.”
Under the agreement, Tripos will develop Web services compatible with the MDL Isentris platform (Isentris domain services), including a domain service based on Tripos’ Concord® product for 3D molecular structure generation. Tripos also plans to ensure that its Benchware line of software for laboratory scientists, including the Benchware Notebook, will be compatible with existing MDL systems, including MDL Isentris and MDL® ISIS, and will feature MDL® Draw chemical rendering software as a preferred Benchware sketching program.
As part of the agreement, the companies expect to work closely with their joint customers to design and develop new discovery informatics applications that leverage both parties’ respective products and services.
“This announcement is great news for the users of Tripos and MDL software, who have long been asking for more integrated discovery informatics solutions as a means to improve day-to-day efficiency and productivity,” added Dr. Walter Reiher, Senior Director, Discovery Informatics, Exelixis, Inc. and former chair of the American MDL Software Users' Group Steering Committee.
Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Dr. Phil McHale
VP, Market & Corporate Communications
Tel: (510) 357-2222 ext. 3541
Director, Marketing Communications
Tel: (314) 951-3208
(Tripos media only)
Waggener Edstrom Bioscience
Tel: (425) 638-7134
This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as “expects,” “anticipates,” “projects,” “estimates,” “intends,” “plans,” “believes,” variations of such words and similar expressions are intended to identify such forward-looking statements. Such statements include the successful integration of Tripos products within Elsevier MDL’s Isentris platform and the adoption of these tools by customers. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Reed Elsevier Group plc and Tripos have identified certain factors that could cause actual results to differ materially from the forward-looking statements in their Annual Report on Form 10-K, their Quarterly Reports on Form 10-Q, and their Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, Reed Elsevier Group and Tripos do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.
Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. MDL and Isentris are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.